Capricor’s Duchenne drug deramiocel receives negative FDA advisory vote on heart outcome

Mindy Leffler, a parent of a young man with Duchenne muscular dystrophy, writes an opinion piece about Capricor’s phase 3 study of its drug deramiocel. She describes her son’s experience living independently while taking the experimental therapy.

The FDA advisory committee recently voted against the drug’s secondary endpoint, which aimed to show a clear benefit in stabilising heart function across the study’s full cohort. The data were described as noisy and failed to demonstrate a definitive effect for boys whose hearts were still stable, though a signal was seen in a subgroup with existing cardiac dysfunction.

Leffler uses the outcome to highlight how rare‑disease trials hinge on countless small design choices. She argues that regulatory flexibility can be applied without compromising scientific rigor, but the recent vote underscores the challenges of proving benefit in heterogeneous patient populations.